- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1459EUR$1,500USD£1,250GBP
- Report
- October 2023
- 190 Pages
Global
From €4768EUR$4,900USD£4,084GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1459EUR$1,500USD£1,250GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1216EUR$1,250USD£1,042GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 70 Pages
Global
From €973EUR$1,000USD£834GBP
- Report
- February 2020
- 231 Pages
Global
From €3503EUR$3,600USD£3,001GBP
- Report
- October 2023
- 105 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- April 2024
- 50 Pages
Global
From €2578EUR$2,650USD£2,209GBP
- Report
- September 2021
- 212 Pages
Global
From €6001EUR$6,168USD£5,141GBP
- Report
- July 2023
- 140 Pages
Global
From €5837EUR$5,999USD£5,000GBP
Somatotropin is a type of endocrine and metabolic disorder drug used to treat growth hormone deficiency. It is a synthetic form of human growth hormone, which is produced naturally in the body and is responsible for growth and development. Somatotropin is used to treat growth hormone deficiency in children and adults, as well as other conditions such as Turner syndrome, Prader-Willi syndrome, and chronic kidney disease. It is also used to treat short stature associated with certain genetic disorders. Somatotropin is administered via injection and is available in both brand-name and generic forms.
Some companies in the Somatotropin market include Pfizer, Novo Nordisk, Eli Lilly, Merck, and Sandoz. Show Less Read more
